Do analysts prefer CVAC or DYN?

Dyne Therapeutics has a consensus price target of $34.17, indicating a potential upside of 39.80%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyne Therapeutics 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.87

Is CVAC or DYN more profitable?

CureVac has a net margin of 199.92% compared to Dyne Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets CureVac 199.92% -23.03% -19.09% Dyne Therapeutics N/A -58.28% -46.77%

Do analysts recommend CVAC or CPRX?

Catalyst Pharmaceuticals has a consensus price target of $32.00, indicating a potential upside of 1.62%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Catalyst Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.56

Do analysts recommend CVAC or RLAY?

Relay Therapeutics has a consensus target price of $24.92, suggesting a potential upside of 35.12%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Relay Therapeutics 2 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.86

Which has stronger valuation & earnings, CVAC or RLAY?

CureVac has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 Relay Therapeutics $10.68M 330.91 -$276.48M -$1.57 N/A

Do analysts recommend DNLI or CVAC?

Denali Therapeutics presently has a consensus target price of $35.17, indicating a potential upside of 52.17%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 1 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.82 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ALMS or CVAC?

Alumis currently has a consensus target price of $40.30, indicating a potential upside of 43.93%. Given Alumis' stronger consensus rating and higher probable upside, equities analysts plainly believe Alumis is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, ALMS or CVAC?

CureVac has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $8.40M 424.87 -$243.32M -$1.98 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Is ALMS or CVAC more profitable?

CureVac has a net margin of 199.92% compared to Alumis' net margin of -2,825.70%. CureVac's return on equity of -23.03% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -2,825.70% -88.79% -70.72% CureVac 199.92% -23.03% -19.09%

CureVac (CVAC) Competitors

$4.66 0.00 (0.00%)

As of 07/24/2026

Compare

CVAC vs. DYN, CPRX, RLAY, DNLI, and ALMS

Should you buy CureVac stock or one of its competitors? MarketBeat compares CureVac with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CureVac include Dyne Therapeutics (DYN), Catalyst Pharmaceuticals (CPRX), Relay Therapeutics (RLAY), Denali Therapeutics (DNLI), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry.

How does CureVac compare to Dyne Therapeutics?

CureVac (NASDAQ:CVAC) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

In the previous week, Dyne Therapeutics had 19 more articles in the media than CureVac. MarketBeat recorded 19 mentions for Dyne Therapeutics and 0 mentions for CureVac. Dyne Therapeutics' average media sentiment score of 0.64 beat CureVac's score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Dyne Therapeutics	Positive

Dyne Therapeutics has a consensus price target of $34.17, indicating a potential upside of 39.80%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

CureVac has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

CureVac has a net margin of 199.92% compared to Dyne Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Dyne Therapeutics	N/A	-58.28%	-46.77%

17.3% of CureVac shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

CureVac and Dyne Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does CureVac compare to Catalyst Pharmaceuticals?

CureVac (NASDAQ:CVAC) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

17.3% of CureVac shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Catalyst Pharmaceuticals had 5 more articles in the media than CureVac. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 0 mentions for CureVac. Catalyst Pharmaceuticals' average media sentiment score of 1.63 beat CureVac's score of 0.00 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Catalyst Pharmaceuticals	Very Positive

Catalyst Pharmaceuticals has a consensus price target of $32.00, indicating a potential upside of 1.62%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Catalyst Pharmaceuticals has higher revenue and earnings than CureVac. CureVac is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

CureVac has a net margin of 199.92% compared to Catalyst Pharmaceuticals' net margin of 37.08%. Catalyst Pharmaceuticals' return on equity of 35.76% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Summary

Catalyst Pharmaceuticals beats CureVac on 14 of the 17 factors compared between the two stocks.

How does CureVac compare to Relay Therapeutics?

CureVac (NASDAQ:CVAC) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Relay Therapeutics has a consensus target price of $24.92, suggesting a potential upside of 35.12%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86

CureVac has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Relay Therapeutics	$10.68M	330.91	-$276.48M	-$1.57	N/A

In the previous week, Relay Therapeutics had 5 more articles in the media than CureVac. MarketBeat recorded 5 mentions for Relay Therapeutics and 0 mentions for CureVac. Relay Therapeutics' average media sentiment score of 0.39 beat CureVac's score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Relay Therapeutics	Neutral

CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market.

17.3% of CureVac shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to Relay Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Relay Therapeutics	N/A	-43.94%	-40.11%

Summary

Relay Therapeutics beats CureVac on 9 of the 17 factors compared between the two stocks.

How does CureVac compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, Denali Therapeutics had 5 more articles in the media than CureVac. MarketBeat recorded 5 mentions for Denali Therapeutics and 0 mentions for CureVac. Denali Therapeutics' average media sentiment score of 0.71 beat CureVac's score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Denali Therapeutics	Positive
CureVac	Neutral

CureVac has a net margin of 199.92% compared to Denali Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
CureVac	199.92%	-23.03%	-19.09%

CureVac has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	11.10	-$512.54M	-$2.88	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Denali Therapeutics presently has a consensus target price of $35.17, indicating a potential upside of 52.17%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Denali Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Summary

Denali Therapeutics beats CureVac on 9 of the 17 factors compared between the two stocks.

How does CureVac compare to Alumis?

Alumis (NASDAQ:ALMS) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

CureVac has a net margin of 199.92% compared to Alumis' net margin of -2,825.70%. CureVac's return on equity of -23.03% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
CureVac	199.92%	-23.03%	-19.09%

17.3% of CureVac shares are held by institutional investors. 33.7% of Alumis shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CureVac has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$8.40M	424.87	-$243.32M	-$1.98	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

In the previous week, Alumis had 4 more articles in the media than CureVac. MarketBeat recorded 4 mentions for Alumis and 0 mentions for CureVac. Alumis' average media sentiment score of 1.20 beat CureVac's score of 0.00 indicating that Alumis is being referred to more favorably in the media.

Company	Overall Sentiment
Alumis	Positive
CureVac	Neutral

Alumis currently has a consensus target price of $40.30, indicating a potential upside of 43.93%. Given Alumis' stronger consensus rating and higher probable upside, equities analysts plainly believe Alumis is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Alumis has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Summary

CureVac beats Alumis on 9 of the 17 factors compared between the two stocks.

Get CureVac News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVAC vs. The Competition

Export

Metric	CureVac	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.05B	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	6.47	21.48	27.14	23.64
Price / Sales	14.78	170.08	517.08	89.50
Price / Cash	4.73	157.90	50.54	59.64
Price / Book	1.39	7.88	10.28	6.07
Net Income	$175.50M	$23.86M	$3.60B	$331.99M
7 Day Performance	N/A	-3.82%	-1.27%	-0.63%
1 Month Performance	N/A	-2.61%	-0.37%	-2.00%
1 Year Performance	-14.65%	32.79%	18.30%	13.62%

CureVac Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
DYN Dyne Therapeutics	3.3037 of 5 stars	$23.74 +1.3%	$34.17 +43.9%	+164.5%	$3.94B	N/A	N/A	100	Upcoming Earnings Analyst Forecast Gap Down
CPRX Catalyst Pharmaceuticals	4.415 of 5 stars	$31.49 flat	$32.00 +1.6%	N/A	$3.86B	$596.96M	18.10	80	News Coverage Short Interest Decrease
RLAY Relay Therapeutics	2.9544 of 5 stars	$19.73 +2.9%	$24.92 +26.3%	+401.1%	$3.77B	$15.35M	N/A	330	News Coverage Analyst Forecast
DNLI Denali Therapeutics	2.6048 of 5 stars	$23.48 +2.5%	$35.08 +49.4%	+61.5%	$3.74B	$330.53M	N/A	430	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVAC) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CureVac (CVAC) Competitors

CVAC vs. DYN, CPRX, RLAY, DNLI, and ALMS

How does CureVac compare to Dyne Therapeutics?

Summary

How does CureVac compare to Catalyst Pharmaceuticals?

Summary

How does CureVac compare to Relay Therapeutics?

Summary

How does CureVac compare to Denali Therapeutics?

Summary

How does CureVac compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CureVac (CVAC) Competitors

CVAC vs. DYN, CPRX, RLAY, DNLI, and ALMS

How does CureVac compare to Dyne Therapeutics?

Which has more risk & volatility, CVAC or DYN?

Does the media refer more to CVAC or DYN?

Do analysts prefer CVAC or DYN?

Which has higher earnings and valuation, CVAC or DYN?

Is CVAC or DYN more profitable?

Do institutionals & insiders believe in CVAC or DYN?

Summary

How does CureVac compare to Catalyst Pharmaceuticals?

Do insiders & institutionals believe in CVAC or CPRX?

Does the media favor CVAC or CPRX?

Do analysts recommend CVAC or CPRX?

Which has higher valuation & earnings, CVAC or CPRX?

Which has more volatility and risk, CVAC or CPRX?

Is CVAC or CPRX more profitable?

Summary

How does CureVac compare to Relay Therapeutics?

Do analysts recommend CVAC or RLAY?

Which has stronger valuation & earnings, CVAC or RLAY?

Does the media favor CVAC or RLAY?

Which has more volatility & risk, CVAC or RLAY?

Do institutionals & insiders hold more shares of CVAC or RLAY?

Is CVAC or RLAY more profitable?

Summary

How does CureVac compare to Denali Therapeutics?

Does the media prefer DNLI or CVAC?

Is DNLI or CVAC more profitable?

Which has preferable valuation & earnings, DNLI or CVAC?

Do institutionals and insiders have more ownership in DNLI or CVAC?

Do analysts recommend DNLI or CVAC?

Which has more volatility and risk, DNLI or CVAC?

Summary

How does CureVac compare to Alumis?

Is ALMS or CVAC more profitable?

Do insiders & institutionals have more ownership in ALMS or CVAC?

Which has better valuation & earnings, ALMS or CVAC?

Does the media prefer ALMS or CVAC?

Do analysts rate ALMS or CVAC?

Which has more risk & volatility, ALMS or CVAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools